{
  "success": true,
  "pagesUsed": [
    0,
    1,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ustekinumab (CNTO1275)",
        "type": {
          "id": "7f2f9df6-dea8-4bcf-826a-bccb6d233df3",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "fcfb3022-b8dd-4657-847e-2bc0967f5772",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Fully human IgG1k monoclonal antibody to human IL-12/23p40.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "7643253b-432e-44bb-8279-8cb8d60f620a",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "e750666e-4f5b-4623-89fd-9bc7c69bf97b",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching IV and SC placebo for blinding.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Oral 5-aminosalicylate (5-ASA)",
        "type": {
          "id": "5fa96e7e-5fd2-45a4-908e-299ba8075097",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "dee30fb2-72bd-4e9e-a948-507d5cf3cba8",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Must be maintained at a stable dose through induction.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Oral corticosteroids",
        "type": {
          "id": "b0e30cf0-cd11-4bbe-9fff-40f2559e68ea",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "1d05fc33-4113-4e16-8258-b3d2b8971080",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Includes prednisone, budesonide, and beclomethasone dipropionate; stable dose required for induction.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Immunomodulators",
        "type": {
          "id": "04421ac7-34c3-42de-a1d9-4990a1b3e914",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "ac3a9448-40e7-40a4-8230-dded5f7cfbdd",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX).",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "TNF-antagonist therapy",
        "type": {
          "id": "108ca5d6-fffa-49f8-8481-887884c6e329",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "6460f1cc-7d24-4d0c-96aa-d9631e168d6f",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Infliximab, adalimumab, golimumab, or approved biosimilars; must be discontinued 8 weeks prior.",
        "administrationIds": [
          "admin_6"
        ]
      },
      {
        "id": "int_7",
        "name": "Vedolizumab",
        "type": {
          "id": "2528e1ab-1103-460b-8c9c-4df847f25054",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "29b2d6ad-0063-4acb-bc72-ca65a1c4a5b3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Anti-alpha4beta7 integrin antagonist; must be discontinued prior to study.",
        "administrationIds": [
          "admin_7"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ustekinumab IV",
        "administrableDoseForm": {
          "id": "0765eb91-d608-4764-a34a-a44451a31615",
          "code": "C42986",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Solution",
          "standardCode": {
            "id": "0a6db99d-7df6-4b00-be6d-89a8913f6e72",
            "code": "C42986",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Solution",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "9d116878-2728-47a1-80ba-c1cf1d7086b7",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "130 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development"
      },
      {
        "id": "prod_2",
        "name": "Ustekinumab SC",
        "administrableDoseForm": {
          "id": "26d86b61-e97f-4fc0-8206-0e595db0f800",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "e6540167-1722-4980-8c6b-bb263f9338cf",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "da47fd2b-3b6f-4953-8271-bffaf021827c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "90 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Induction Fixed Dose",
        "instanceType": "Administration",
        "dose": "130 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_2",
        "name": "Induction Weight-based (<=55 kg)",
        "instanceType": "Administration",
        "dose": "260 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_3",
        "name": "Induction Weight-based (>55 kg to <=85 kg)",
        "instanceType": "Administration",
        "dose": "390 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_4",
        "name": "Induction Weight-based (>85 kg)",
        "instanceType": "Administration",
        "dose": "520 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Week 0"
      },
      {
        "id": "admin_5",
        "name": "Maintenance q8w",
        "instanceType": "Administration",
        "dose": "90 mg",
        "doseFrequency": "Every 8 weeks",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Through Week 44"
      },
      {
        "id": "admin_6",
        "name": "Maintenance q12w",
        "instanceType": "Administration",
        "dose": "90 mg",
        "doseFrequency": "Every 12 weeks",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Through Week 44"
      },
      {
        "id": "admin_7",
        "name": "Late Responder Induction",
        "instanceType": "Administration",
        "dose": "90 mg",
        "doseFrequency": "Once",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Week 8 (for non-responders at Week 8)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Ustekinumab",
        "instanceType": "Substance",
        "description": "Anti-IL-12/23p40 monoclonal antibody"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 7,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ustekinumab (CNTO1275)",
        "role": "Investigational Product",
        "description": "Fully human IgG1k monoclonal antibody to human IL-12/23p40."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching IV and SC placebo for blinding."
      },
      {
        "name": "Oral 5-aminosalicylate (5-ASA)",
        "role": "Background Therapy",
        "description": "Must be maintained at a stable dose through induction."
      },
      {
        "name": "Oral corticosteroids",
        "role": "Background Therapy",
        "description": "Includes prednisone, budesonide, and beclomethasone dipropionate; stable dose required for induction."
      },
      {
        "name": "Immunomodulators",
        "role": "Background Therapy",
        "description": "Azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX)."
      },
      {
        "name": "TNF-antagonist therapy",
        "role": "Concomitant Medication",
        "description": "Infliximab, adalimumab, golimumab, or approved biosimilars; must be discontinued 8 weeks prior."
      },
      {
        "name": "Vedolizumab",
        "role": "Concomitant Medication",
        "description": "Anti-alpha4beta7 integrin antagonist; must be discontinued prior to study."
      }
    ],
    "products": [
      {
        "name": "Ustekinumab IV",
        "doseForm": "Solution",
        "strength": "130 mg",
        "manufacturer": "Janssen Research & Development"
      },
      {
        "name": "Ustekinumab SC",
        "doseForm": "Injection",
        "strength": "90 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "substances": [
      {
        "name": "Ustekinumab",
        "description": "Anti-IL-12/23p40 monoclonal antibody"
      }
    ],
    "administrations": [
      {
        "name": "Induction Fixed Dose",
        "dose": "130 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Induction Weight-based (<=55 kg)",
        "dose": "260 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Induction Weight-based (>55 kg to <=85 kg)",
        "dose": "390 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Induction Weight-based (>85 kg)",
        "dose": "520 mg",
        "frequency": "Once",
        "route": "Intravenous",
        "duration": "Week 0"
      },
      {
        "name": "Maintenance q8w",
        "dose": "90 mg",
        "frequency": "Every 8 weeks",
        "route": "Subcutaneous",
        "duration": "Through Week 44"
      },
      {
        "name": "Maintenance q12w",
        "dose": "90 mg",
        "frequency": "Every 12 weeks",
        "route": "Subcutaneous",
        "duration": "Through Week 44"
      },
      {
        "name": "Late Responder Induction",
        "dose": "90 mg",
        "frequency": "Once",
        "route": "Subcutaneous",
        "duration": "Week 8 (for non-responders at Week 8)"
      }
    ],
    "devices": []
  }
}